Oncology

Research and development in targeted therapies

Cancer has become an increasing global burden, and research is currently under way to determine epidemiology within the Middle East and North Africa (MENA) region. Cancers that are considered common in the region include breast cancer, lung cancer, hepatocellular carcinoma, prostate and colorectal cancer.

New therapeutic targets are providing cancer patients with improved outcomes and better quality of life. Boehringer Ingelheim is committed to developing targeted therapies for solid tumours and haematological malignancies and our oncology research focuses on three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition.